cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Instil Bio Inc
16 own
11 watching
Current Price
$23.44
$-0.69
(-2.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
65.43M
52-Week High
52-Week High
92
52-Week Low
52-Week Low
9.62000
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
28
iconMarket Capitalization65.43M
icon52-Week High92
icon52-Week Low9.62000
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio28
What does the Instil Bio Inc do?
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
Read More
How much money does Instil Bio Inc make?
News & Events about Instil Bio Inc.
Globe Newswire
1 year ago
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage ...
Globe Newswire
2years ago
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding potential financing or...
Globe Newswire
2years ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (Instil Bio or the Company) (NASDAQ: TIL) on behalf of Instil Bio stockholders. Our investigation concerns whether ...
Market News Video
2years ago
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 0.4%. Leading the group were shares of Instil Bio, up about 19.7% and shares of Relmada Therapeutics up about 17.4% on the day...
Globe Newswire
2years ago
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PROG Holdings, Inc. (NYSE: PRG), Fox Corporation (NASDAQ: FOX, FOXA), Instil Bio, Inc. (NASDAQ: TIL), and Twist Bioscience Corp (...
Frequently Asked Questions
Frequently Asked Questions
What is Instil Bio Inc share price today?
plus_minus_icon
Can Indians buy Instil Bio Inc shares?
plus_minus_icon
How can I buy Instil Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Instil Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Instil Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Instil Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Instil Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Instil Bio Inc?
plus_minus_icon
What percentage is Instil Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Instil Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.44
$-0.69
(-2.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.02
$0.03 (2.72 %)
Precision BioSciences Inc
Precision BioSciences Inc
$5.08
$0.08 (1.60 %)
Veru Inc
Veru Inc
$1.21
$-0.07 (-5.47 %)
Rapt Therapeutics Inc
Rapt Therapeutics Inc
$1.18
$-0.01 (-0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.02
$0.03 (2.72 %)
Precision BioSciences Inc
Precision BioSciences Inc
$5.08
$0.08 (1.60 %)
Veru Inc
Veru Inc
$1.21
$-0.07 (-5.47 %)
Rapt Therapeutics Inc
Rapt Therapeutics Inc
$1.18
$-0.01 (-0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00